.After a handful of years in biotech, Mike Quigley, Ph.D., is returning to the pharma layer, using up the leading scientific research area at Sanofi.Quigley will certainly begin Sept. 30 as the French Big Pharma's main clinical police officer and also international head of research, Sanofi told Intense Biotech in an emailed statement.Quigley is actually changing Frank Nestle, M.D., that left behind Sanofi this spring amidst an international overhaul of the firm's R&D system. Nestle, who invested eight years with the pharma, jumped over to Deerfield Control, where he presently works as a partner on the rehabs group as well as CEO of the company's curative exploration and also progression procedures.
Quigley will definitely join Sanofi coming from a San Francisco-based biotech that resides in secrecy, depending on to his LinkedIn profile page. He's currently specified as the provider's co-founder, president and also chief executive officer.Given that August 2021, Quigley has served as a project companion at SV Health and wellness Investors, a health care fund manager with present assets in biotechs such as BioAge, Cerevance, Dualitas Therapies and also Nimbus Rehabs, to name a few. Quigley formerly held the top location at Dualitas, a biotech that remains in stealth, according to STAT.The soon-to-be Sanofi innovator also recently helmed Therini Bio, an immunotherapy biotech functioning to establish treatments for neurodegenerative ailments driven by vascular dysfunction.Just before devoting the last couple of years in biotech, Quigley possesses an also longer track record in Big Pharma, most lately functioning as Gilead's elderly bad habit president of research study the field of biology until the summer months of 2021. Before that, he clocked in much more than 4 years across various management jobs at Bristol Myers Squibb and acted as a scientific supervisor at Johnson & Johnson's Janssen upper arm before that.Sanofi stated Quigley's mission in his new function will be to "optimize our possibility of results through superior collaborations throughout our company as well as past, delivering best-in-class development in addition to establishing and sourcing brand new industry-leading talent with a dedication to variety," depending on to an inner memo obtained through STAT.